Natto is a traditional food from Japan that is made out of fermented soybeans. It is rich in amino acids and vitamins. Much has been done to explore the health-promoting effects of natto. A recently conducted cohort study reported that consumption of fermented soybeans was directly correlated with a decrease in mortality rate in Japan. This correlation was not observed in consumption of non-fermented soybeans. The fermentation process in natto is made possible by the bacterium, Bacillus subtilis var. natto.
Plasmanex1 is a dietary supplement whose main ingredient is bacillopeptidase F Proprietary Blend (BFPB), a serine protease derived from Bacillus subtilis var. natto. Prior studies on Plasmanex1 have shown its anti-coagulant properties and its role in protecting against thromboembolism. It has been reported to improve muscle stiffness, decrease headache and increase skin surface temperature, suggesting it may support enhanced blood flow. In a recent study by Dr. Fred Pescatore, subjects with metabolic disorders were given 250 mg of Plasmanex1 daily for 12 weeks. The results showed it promoted healthy LDL cholesterol, triglyceride and total cholesterol levels. Some subjects had their total cholesterol and LDL cholesterol go down to normal levels. In addition, HbA1C (blood glucose level), hs-CRP (high sensitivity-C reactive protein) and body weight were noted to be significantly reduced. Fibrinogen levels were also significantly decreased. In some subjects, the fibrinogen levels returned to within normal range.
The results from Dr. Pescatore’s study showed that Plasmanex1 has the likelihood to improve lipid metabolism as seen in the maintenance of healthy total cholesterol, LDL cholesterol and triglyceride levels. Glycated hemoglobin or HbA1c is a marker of one’s blood glucose level within the last three months. It is a good indicator of the risk for diabetes and its complications. The observed significant decrease in HbA1c indicates that Plasmanex1 has the potential to improve blood sugar levels which could especially benefit those with diabetes blood sugar issues. The observed decrease in hs-CRP levels indicates that of Plasmanex1.can manage inflammation. The results also revealed its body-weight reducing potential. The decrease in fibrinogen levels suggests the role of Plasmanex1 in anti-coagulation which may be especially helpful in those at risk of blood viscosity disorders. Increased blood viscosity may cause unnecessary blood clots leading to various diseases.
Metabolic syndrome affects about a quarter of the world population. It involves abnormalities in blood glucose, cholesterol and triglyceride levels as well as increased weight and blood pressure. Abnormalities in these metabolic markers increases one’s health risk. These risks are also called lifestyle diseases because they are associated with lack of physical activity, high calorie and low fiber diet, smoking, as well as drugs and alcohol intake. Studies have shown the potential of Plasmanex1 to improve metabolic markers, thereby reducing the risk of metabolic syndrome and all the other associated maladies. Given the high worldwide prevalence of metabolic syndrome, Plasmanex1 holds much promise in maintaining overall health.
Plasmanex1 is available in the US through Daiwa Health Development.
Pescatore, Fred. “Plasmanex1 - A Functional Food for Metabolic Disorders.” Townsend Letter, The Examiner of Alternative Medicine, no. 445-46, 2020, www.townsendletter.com/article/445-46-plasmanex1-natto-functional-food/.